• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BioAtla Inc. (Amendment)

    2/9/24 4:58:18 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BCAB alert in real time by email
    SC 13G/A 1 bioatla-jayshort_13ga.htm BIOATLA, INC. JAY SHORT 13G/A





    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*
    BioAtla, Inc.
    (Name of Issuer)
     
     
     
    Common Stock, par value $0.0001
    (Title of Class of Securities)
     
     
     
    09077B104
    (CUSIP Number)
     
     
     
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)
     
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐ Rule 13d-1(b)
    ☐ Rule 13d-1(c)
    ☒ Rule 13d-1(d)
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. 

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    SCHEDULE 13G
    CUSIP No. 09077B104
     

    1
    NAMES OF REPORTING PERSONS
       
    Jay M. Short
       
       
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
       
    3
    SEC USE ONLY
       
         
       
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
    United States of America
       
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
       
    2,103,542 (includes 405,532 shares underlying options that are exercisable within 60 days of December 31, 2023)
       
       
    6
    SHARED VOTING POWER
       
    1,354,648 (of which 1,354,598 shares are owned or controlled by Dr. Short’s spouse as to which he disclaims beneficial ownership, except to the extent of his pecuniary interest therein, if any)
       
       
    7
    SOLE DISPOSITIVE POWER
       
    2,103,542 (includes 405,532 shares underlying options that are exercisable within 60 days of December 31, 2023)
       
       
    8
    SHARED DISPOSITIVE POWER
       
    1,354,648 (of which 1,354,598 shares are owned or controlled by Dr. Short’s spouse as to which he disclaims beneficial ownership, except to the extent of his pecuniary interest therein, if any)
       
       
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    3,458,190
       
       
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    ☐
       
       
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
    7.2%
       
       
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
    IN
       
       

    CUSIP No. 09077B104
     

    1
    NAMES OF REPORTING PERSONS
       
    Himalaya Parent LLC
       
       
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
       
    3
    SEC USE ONLY
       
         
       
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
       
    Delaware
       
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
       
    ‑ 0 ‑
       
       
    6
    SHARED VOTING POWER
       
    50
       
       
    7
    SOLE DISPOSITIVE POWER
       
    ‑ 0 ‑
       
       
    8
    SHARED DISPOSITIVE POWER
       
    50
       
       
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
    50
       
       
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
    ☐
       
       
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
    0.0%
       
       
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
    OO – limited liability company
       


    Item 1(a).
    Name of Issuer:
      BioAtla, Inc.

       
    Item 1(b).
    Address of Issuer's Principal Executive Offices:
      11085 Torreyana Road, San Diego, California 92121

       
    Item 2(a).
    Name of Person Filing:
     
    (1)  Jay M. Short
    (2) Himalaya Parent LLC
    Item 2(b).
    Address of Principal Business Office or, if none, Residence:
    (1) Jay M. Short
    c/o BioAtla, Inc.
    11085 Torreyana Road
    San Diego, California 92121
    (2) Himalaya Parent LLC
    c/o BioAtla, Inc.
    11085 Torreyana Road
    San Diego, California 92121
    Item 2(c).
    Citizenship:
    (1)  Jay M. Short: United States of America
    (2) Himalaya Parent LLC: Delaware
       
    Item 2(d).
    Title of Class of Securities:
      Common Stock, par value $0.0001

       
    Item 2(e).
    CUSIP Number:
      09077B104

       
    Item 3.
    If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
      240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

     
    (a)
    ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
     
    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
     
    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
     
    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
    (e)
    ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);
     
    (f)
    ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);
     
    (g)
    ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);
     
    (h)
    ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
    (i)
    ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
    (j)
    ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);
     
    (k)
    ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable.
    Item 4.
    Ownership.
     
    (a)
    Amount beneficially owned:
       
    (1) Jay M. Short: 3,458,190
    (2) Himalaya Parent LLC: 50


    (1) As of the date hereof, Dr. Short beneficially owns 3,458,190 shares of common stock of the Issuer. This amount includes: (i) 1,844,815 shares held by Dr. Short, which includes 405,532 shares of common stock that are issuable upon exercise of outstanding options within sixty days of December 31, 2023; (ii) 258,727 shares held by Jay Short 2020 Irrevocable Gift Trust, which Dr. Short is the trustee of and holds sole voting and dispositive power with respect to the shares; (iii) 793,547 shares held by Carolyn Anderson Short, Dr. Short’s spouse, as to which Dr. Short disclaims beneficial ownership, except to the extent of his pecuniary interest therein, if any; (iv) 258,727 shares held by Carolyn Short 2020 Irrevocable Gift Trust, as to which Dr. Short disclaims beneficial ownership, except to the extent of his pecuniary interest therein, if any; (v) 302,324 shares held by Capia IP, LLC, which Carolyn Anderson Short is the managing member of and as to which Dr. Short disclaims beneficial ownership, except to the extent of his pecuniary interest therein, if any; and (vi) 50 shares held by Himalaya Parent LLC, which Dr. Short and Carolyn Anderson Short are the managers of and as to which Dr. Short and Carolyn Anderson Short disclaim beneficial ownership of except to the extent of his or her pecuniary interest therein.





    Dr. Short is the Co-founder, Chairman and Chief Executive Officer of the Issuer and Ms. Anderson Short is Dr. Short’s spouse.
     
    (b)
    Percent of class:
       
    (1) Jay M. Short: 7.2%
    (2) Himalaya Parent LLC: 0.0%
         
        The above percentages are calculated in accordance with Rule 13d-3 based on 48,077,599 issued and outstanding shares of common stock of the Issuer as of December 31, 2023.

     
    (c)
    Number of shares as to which the person has:
     
    (i)
    Sole power to vote or to direct the vote:
       
    (1)Jay M. Short: 2,103,542
    (2)Himalaya Parent LLC: 0

     
    (ii)
    Shared power to vote or to direct the vote:
       
    (1)Jay M. Short: 1,354,648
    (2)Himalaya Parent LLC: 50

     
    (iii)
    Sole power to dispose or to direct the disposition of:
       
    (1)Jay M. Short: 2,103,542
    (2)Himalaya Parent LLC: 0

     
    (iv)
    Shared power to dispose or to direct the disposition of:
       
    (1)Jay M. Short: 1,354,648
    (2)Himalaya Parent LLC: 50

       
    Item 5.
    Ownership of Five Percent or Less of a Class.
    Not applicable.
       
    Item 6.
    Ownership of More Than Five Percent on Behalf of Another Person.
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not applicable.
       
    Item 8.
    Identification and Classification of Members of the Group.
    Not applicable.
       
    Item 9.
    Notice of Dissolution of Group.
    Not applicable.
       
    Item 10.
    Certification.
     
    (a) Not applicable.
    (b) Not applicable.


    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

       
       
         
    Dated: February 9, 2024
    Jay M. Short
       
     
    By:
     /s/ Jay M. Short
       
    Name: Jay M. Short
     
     
         
       
    Dated: February 9, 2024
    Himalaya Parent LLC
       
     
    By:
     /s/ Jay M. Short
       
    Name: Jay M. Short
    Title:   Manager
     
     










    Get the next $BCAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCAB

    DatePrice TargetRatingAnalyst
    11/13/2024Buy → Neutral
    H.C. Wainwright
    9/15/2022$17.00Mkt Outperform
    JMP Securities
    5/5/2022$35.00 → $5.00Outperform → Neutral
    Credit Suisse
    3/21/2022$25.00Buy
    H.C. Wainwright
    10/15/2021$68.00Buy
    BTIG Research
    6/28/2021$75.00Buy
    ROTH Capital
    More analyst ratings

    $BCAB
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by BioAtla Inc.

      SCHEDULE 13G/A - BioAtla, Inc. (0001826892) (Subject)

      5/20/25 2:26:28 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - BioAtla, Inc. (0001826892) (Filer)

      5/16/25 5:05:56 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by BioAtla Inc.

      424B3 - BioAtla, Inc. (0001826892) (Filer)

      5/16/25 4:22:32 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Vasquez Christian was granted 85,000 shares, increasing direct ownership by 44% to 276,696 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      3/13/25 4:12:55 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Short Jay M Phd was granted 431,000 shares, increasing direct ownership by 24% to 2,256,372 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      3/13/25 4:12:28 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Waldron Richard A was granted 100,000 shares, increasing direct ownership by 43% to 333,263 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      3/13/25 4:12:02 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Leadership Updates

    Live Leadership Updates

    See more

    $BCAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BCAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $BCAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS

      SAN DIEGO, Dec. 21, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Edward L. (Eddie) Williams has been appointed to the BioAtla Board of Directors and has agreed to serve on the Audit Committee of the Board.  Mr. Williams has extensive executive experience in the biopharmaceutical industry and as a member of the board of directors of a biotechnology company in late-stage clinical development. Jay M. Short, Ph.D., Chairman of the Board and Chief Executive Officer, stated, "Eddie's career of demonstrated success and knowledge in growing biopharmaceuti

      12/21/21 9:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mcbrinn Sylvia bought $9,400 worth of shares (4,000 units at $2.35), increasing direct ownership by 26% to 19,125 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      1/19/24 4:21:50 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mcbrinn Sylvia bought $9,320 worth of shares (4,000 units at $2.33), increasing direct ownership by 36% to 15,125 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      12/26/23 7:43:02 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Short Jay M Phd bought $106,910 worth of shares (50,000 units at $2.14), increasing direct ownership by 4% to 1,439,283 units (SEC Form 4)

      4 - BioAtla, Inc. (0001826892) (Issuer)

      12/20/23 6:27:44 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla downgraded by H.C. Wainwright

      H.C. Wainwright downgraded BioAtla from Buy to Neutral

      11/13/24 7:31:56 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JMP Securities initiated coverage on BioAtla with a new price target

      JMP Securities initiated coverage of BioAtla with a rating of Mkt Outperform and set a new price target of $17.00

      9/15/22 7:31:28 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla downgraded by Credit Suisse with a new price target

      Credit Suisse downgraded BioAtla from Outperform to Neutral and set a new price target of $5.00 from $35.00 previously

      5/5/22 6:12:47 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BioAtla Inc.

      SC 13G/A - BioAtla, Inc. (0001826892) (Subject)

      11/14/24 4:00:05 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

      SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

      10/2/24 4:30:04 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by BioAtla Inc.

      SC 13D/A - BioAtla, Inc. (0001826892) (Subject)

      9/6/24 4:59:38 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Financials

    Live finance-specific insights

    See more
    • BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

      CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fas

      5/6/25 4:05:00 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

      SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025 and provide business highlights. Conference Call and Webcast Information        Date: Tuesday, May 6, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)Con

      4/29/25 8:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

      CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) with 66% and 58% of patients with mKRAS NSCLC alive at a landmark one-year and two-years, respectively, which exceeds the reported standard of care Ozuriftamab vedotin (CAB-ROR2-ADC) demonstrated compelling anti-tumor activity in treatment-refractory, metastatic HPV-positive squamous cell carcinoma of the head and neck (SCCHN); a population which is poorly served by EGFR inhibitorsCash balance of $49mm at year-end 2024 with recent cost-redu

      3/27/25 4:05:00 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BCAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

      CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark survival of 59% in mKRAS non-small cell lung cancer (NSCLC); Previous studies have reported 2-year landmark survival less than 20% among patients treated with standard of care agentsOzuriftamab vedotin (Oz-V; CAB-ROR2-ADC) Phase 2 study continues to demonstrate compelling signals in HPV-positive squamous cell carcinoma of the head and neck (SCCHN) patients; Company utilizing Fas

      5/6/25 4:05:00 PM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla to Participate in the Citizens Life Sciences Conference

      SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company's management will provide a corporate update and participate in one-on-one investor meetings at the Citizens Life Sciences Conference, to be held in New York, NY May 7-8, 2025. Format: Corporate update and one-on-one investor meetingsDate: Wednesday, May 7, 2025Time: 10:00 a.m. ETLocation: New York, NYWebcast Link: Click Here About BioAtla®, Inc.BioAtla is a global clinical-stage biotechnology company with operation

      4/30/25 8:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

      SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025 and provide business highlights. Conference Call and Webcast Information        Date: Tuesday, May 6, 2025Time: 4:30 p.m. ETWebcast Link: BioAtla First Quarter 2025 Earnings Conference Call Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)Con

      4/29/25 8:00:00 AM ET
      $BCAB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care